

ORIGINAL ARTICLE**Detection of *Nocardia*, *Streptomyces* and *Rhodococcus* from broncho-alveolar lavage specimens of patients with HIV by Multiplex PCR Assay**

Hossein Ali Rahdar^{1,2}, Mohammad Reza Salehi³, Abass Bahador¹, Seyedesomaye Jasemi¹, Morteza Karami-Zarandi¹, Malehe Hasan Nejad³, Shahram Shahraki-Zahedani⁴, Jafar Amani⁵, Seifu Gizaw Feyisa^{1,6}, Jalil Kardan-Yamchi¹, Mohammad Mehdi Feizabadi^{1*}

OPEN ACCESS

Citation: Hossein Ali Rahdar, Mohammad Reza Salehi, Abass Bahador, *et al.* Detection of *Nocardia*, *Streptomyces* and *Rhodococcus* from broncho-alveolar lavage specimens of patients with HIV by multiplex PCR assay. *Ethiop J Health Sci.* 2019; 29(6):737. doi:<http://dx.doi.org/10.4314/ejhs.v29i6.10>

Received: June 28, 2019

Accepted: July 27, 2019

Published: November 1, 2019

Copyright: ©2019 Hossein Ali Rahdar, *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by Tehran University of Medical Sciences (Project No.36924).

Competing Interests: The authors declare that this manuscript was approved by all authors in its form and that no competing interest exists.

Affiliation and Correspondence:

¹Department of Medical Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

²Department of Microbiology, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran

³Department of Infectious and Tropical Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

⁴Department of Medical Microbiology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

⁵Baqiyatallah University of Medical Sciences, Tehran, Iran.

⁶Department of Biology, College of Natural Sciences, Jimma University, Ethiopia

*Email: mfeizabadi@tums.ac.ir

ABSTRACT

Background: *Nocardia*, *Streptomyces* and *Rhodococcus* are life threatening opportunistic pathogens under immunodeficiency conditions, particularly among patients infected with HIV. Rapid and accurate detection of these infections can improve immune health quality, patient management and appropriate treatment. The aim of this study was to design a novel multiplex-PCR assay for rapid diagnosis of these three organisms directly from broncho-alveolar lavage (BAL) specimens of patients infected with HIV.

Methods: The genus specific primers were designed for direct-detection of *Nocardia*, *Streptomyces* and *Rhodococcus* in a single tube multiplex PCR. This PCR specifically amplified the target genes from pure cultures. It subsequently was applied on BAL specimens of 29 HIV positive patients that had previously been culture negative for actinomycete bacteria, of which *Nocardia*, *Streptomyces* and *Rhodococcus* are members.

Results: Of 29 respiratory clinical specimens, there were positive for *Nocardia* spp. and one was positive for *Streptomyces* spp using the multiplex PCR assay. The sequencing of the PCR products identified the species as *Nocardia cyriacigeorgica* (n=2), *Nocardia farcinica* and *Streptomyces albus*.

Conclusion: This novel multiplex PCR assay yielded reliable results for accurate identification of *Nocardia*, *Streptomyces* and *Rhodococcus* from BAL while the results of bacterial culture were negative.

Keywords: *Nocardia*; *Streptomyces*; *Rhodococcus*; HIV; Infection; Multiplex PCR.

INTRODUCTION

In recent years, the incidence of opportunistic infections has increased in individuals with underlying conditions, autoimmune diseases, cancers, HIV, organ transplantation and chemotherapy. Among opportunistic pathogens, members of actinomycetes order such as *Nocardia*, *Streptomyces* and *Rhodococcus* need to be identified correctly prior to starting antibiotic therapy (1,2).

Pulmonary nocardiosis is an invasive infection caused by the genus *Nocardia*, a partial acid-fast microorganism. The common route of pulmonary infection is inhalation of contaminated aerosols from environmental sources. Therefore, the lung is the most common organ involved in nocardiosis. Other entry routes include direct bacterial inoculation of the skin and eyes (1,3). *Nocardia* species may be transmitted to immunocompromised individuals through contact with environmental sources, leading to various complications, from local cutaneous lesions to disseminated infections (3).

Streptomyces spp. are gram-positive filamentous bacteria that live in a wide range of environmental sources and can produce antimicrobial compounds and secondary metabolites. This group of bacteria may cause opportunistic infections such as pulmonary disease, tuberculosis mimicking, and mycetoma in immunocompromised patients (4).

Rhodococcus spp. are saprophytic members of *Nocardiaceae* that live in environmental sources including soil, dust, decaying plants, milk and animals. The first case of infection with *Rhodococcus equi* was reported in 1967 by Golub *et al.* from lung abscess of a patient with AIDS (5,6). In addition, there are several clinical reports of human infections with *R. erythropolis*, *R. ruber*, *R. gordoniae*, and *R. fascians*. However, *R. equi* has been the predominant species causing infections among rhodococci (5,7). Nowadays, the incidence rate of infections with *Rhodococcus* species are increasing due to an increasing number of individuals with immune-disorders and the development of microbiology methods to detect these bacteria (5,8,9).

We are at the end of the third decade of the acquired AIDS pandemic (10). According to the literature, the number of opportunistic infections, particularly aerobic-actinomyces infection in HIV-infected patients has increased (11). Although, culture is a gold standard method for laboratory diagnosis of bacterial diseases, this method is not robust because of the slow growing of the actinomycete bacteria and complexity of their nutritional requirement (12). In addition, it cannot differentiate between clinical symptoms of pneumonia; skin, sub-cutaneous and brain

abscesses caused by actinomycetes from tuberculosis, viral, fungi infection or malignant tumours (3). Moreover, the sensitivity of direct smear microscopy and culture is low and controversial as it interferes with prior use of antibiotics before sampling (1,13). These methods are also time consuming, expensive and need technical skill. Therefore, application of rapid, inexpensive and reliable diagnostic methods is essential for diagnosis and management of these infections. Previously, PCR was used in another study for the diagnosis of these infections in separate single tubes (14,15). The aim of this study was to design a novel multiplex-PCR assay for simultaneous identification of *Nocardia* and *Streptomyces* and *Rhodococcus* genera infections from broncho-alveolar lavage (BAL) specimens of HIV-infected patients in a single tube.

MATERIALS AND METHODS

Culturing of specimens: This study was performed between November 2018 and March 2019 at the Imam Khomeini Complex Hospital (IKH), Tehran University of Medical Sciences (Tehran, Iran). Totally, 29 clinical respiratory specimens including one lung biopsy as well as 28 BAL specimens were collected during routine bronchoscopy from complicated pulmonary infections of HIV patients excluding pulmonary-tuberculosis. The specimens were sent to the Department of Molecular Microbiology laboratory at Tehran University of Medical Sciences immediately and divided into two tubes.

The specimens in the first tube were cultured on brain-heart infusion (BHI) agar medium containing polymyxin B (5 mg/liter), vancomycin (5 mg/liter) and cycloheximide (5 mg/liter) and incubated for 2 to 4 weeks at 30 and 37°C (3). Direct smear was prepared on slides and specimens were stained with partially acid-fast and Gram staining using the specimens from the first tube. The specimens in the second tube were used for PCR assay.

This study has been approved by the ethical committee of Tehran University of Medical Sciences (approval number, IR.TUMS.MEDICINE.REC.1397.261).

Primer design: The *gyrB* gene sequences were retrieved from NCBI Gene Bank for the various

genera including *Dietzia*, *Gordonia*, *Mycobacterium*, *Nocardia*, *Rhodococcus*, *Streptomyces*, and *Tsukamurella* to design genus specific primers pairs. Several *gyrB* gene sequences were obtained for every genus. The sequences were analysed by Oligo 5 Software and signature sequences for each genus were selected.

A pair of primers was designed for pathogenic genera of *Streptomyces*. By modifications in existing primers, pairs of specific primers were designed for *Nocardia* and *Rhodococcus equi* (Table 1) (16,17).

Table 1. Primers designed for *Nocardia* (NR), *Streptomyces* (Stp) and *Rhodococcus equi* (R).

Primer	Sequence	Length of product	genus
Stp-F	GTGCTGTGCCAGAAAGGGCG	320 bp	<i>Streptomyces</i> spp.
Stp-R	GCGAGGATCGTGACGTCGAT		
NR-F	CGACCACAAGGGGGCCTA	596 bp	<i>Nocardia</i> spp.
NR-R	GGTTGTAAACCTCTTTCGACAGG		
R-F	TCCAGAAGCGGGATGAGGAT	707 bp	<i>Rhodococcus</i> spp.
R-R	TGGTGTGATGGCGGAAGATC		

Specificity of the PCR assay: Samples used: DNA from 33 clinical isolates of *Nocardia* species (n=10), *Nocardiosis* species (n=2), *Streptomyces* species (n=2), *Rhodococcus equi* (n=1), different species of non-tuberculosis mycobacteria (n=4), *Mycobacterium tuberculosis s*(n=2), *Klebsiella pneumoniae* (n=3), *Acinetobacter baumannii* strains (n=3), *Pseudomonas aeruginosa* (n=3), *Staphylococcus aureus* (n=3), *Nocardia cyriacigeorgica* (DSM44484), *N. asteroides* (ATCC19247) and *N. otitidiscaviarum* (ATCC14629) were tested to determine the specificity of the multiplex PCR.

DNA extraction: Chromosomal DNA was extracted using the simple boiling method. In brief, several colonies of bacteria were added to 200 ml TE buffer. Subsequently, the suspension was boiled for 30 min and centrifuged at 11,000 g for 10 min. The supernatant was transferred to another sterile micro tube and centrifuged at 20,000 g for 10 min. The DNA-pellet was re-suspended in 50 µl Milli-Q water and stored at -20 °C (3) for molecular assay.

PCR amplification: PCR was carried out in reaction mixture containing 12.5 µL master mix

(Ampliqon Co, Denmark) that contained 1X PCR buffer, 1.5 mM MgCl₂, 1 µL template DNA (1µg), 0.15 mM dNTP, 1.25 U Taq DNA polymerase, 1µL of each forward and reverse primers (Table 1) and sterile distilled water up to 25 µL. PCR was performed in a GenAmp PCR system (BIORAD, USA) according to the following program: pre-denaturation at 94°C for 5 min followed by 33 cycles each containing denaturation at 94°C for 45 s, annealing at 62°C for 45 s and extension at 72°C for 60 s, followed by a final extension at 72°C for 5 min. In addition, *Nocardia cyriacigeorgica* (DSM44484) was used as a positive control and a mixture reaction containing all of the reagents except template were used as a negative control. The PCR products were loaded on 1.5% agarose gel containing DNA safety and run by electrophoresis for 1 h at 85 V and 25 mA. The gel was visualized under UV trans illuminator after electrophoresis. Finally, the samples positive were sequenced.

Multiplex PCR and sequencing of clinical samples: In total, 1-2 mL of BAL samples was sent to the Department of Molecular Microbiology laboratory after extraction during bronchoscopy

(7). In order to extract DNA from the second tube of BAL specimen, 100 μ L of BAL samples was suspended in 250 μ L of sterile distilled water and then DNA was extracted using MTB respiratory specimen preparation kit (Invitek, USA).

Multiplex PCR was performed as above using specific primers for the genera of *Nocardia*, *Streptomyces* and *Rhodococcus equi* for direct identification of these pathogens from BAL samples. Positive results from the gel were confirmed by DNA sequencing. Sequences were compared with those stored in GenBank using BLAST alignment software. Similarity greater than 99% was considered as a single species.

Clinical data collection: Patient's demographic data such as age, gender, BAL leukocyte count, co-trimoxazole consumption, C-reactive protein, alveolar cavitation and other clinical signs were collected, according to privacy and ethical

principles. After sequencing, treatment choices in respect to the bacteria detected were documented, along with the follow-up of the patient (discussed in the *Discussion* section).

RESULTS

Specificity testing of the method

Study population of bacterial samples: In total, 28 BAL specimens and one lung biopsy from HIV-infected patients (18 men and 11 women; mean age: 41 years old) were collected by bronchoscopy for diagnosis of aerobic actinomycetes infection (particularly *Nocardiosis*) (Table 2). Twelve patients had started therapy by low dosage of co-trimoxazole prophylaxis before sampling of bronchoscopy. All specimens were negative in culture, although two specimens were positive in direct smear microscopy.

Table 2. Main characteristics of study population (n=29). BAL, broncho-alveolar lavage. A detailed version of this table is available as *Underlying data*.

	Multiplex-PCRBALs+lung biopsy negative	Multiplex-PCR BALs+lung biopsy positive
Male	15	3
Female	10	1
Median age (years)	41	41
Cotrimoxazole prophylaxis (n)	11	1
<i>Blood tests at time of BAL</i>		
Median white blood cell count (x1000/ μ L)	6.2	7.1
Median neutrophil count (x1000/ μ L)	3.7	5.1
Median lymphocyte count (x1000/ μ L)	1.6	1.1
Median CRP concentration (mg/L)	5.1	3.2
PCR result (n)	25	4
<i>Clinical/radiological presentation (n)</i>		
Pulmonary cavity	8	2
Pulmonary abscess	1	2
Chronic bronchopulmonary	6	4
Brain abscess	2	1

Multiplex PCR assay and sequencing: From 29 negative culture specimens, 4 showed positive results in multiplex PCR assay including 3 specimens that were positive for *Nocardia* and one

for *Streptomyces* species. The sizes of PCR products were 596 bp (*Nocardia* spp.), 320bp (*Streptomyces* spp.) and 707 bp (*Rhodococcus* spp.) (Figure 1).




Figure 1 Multiplex-PCR - amplified products in 1% agarose gel; *Nocardia* (596bp), *Streptomyces* (320 bp), *Rhodococcus* (707 bp), and M, molecular size markers (100-bp ladder).

Sequencing of products (n=4) identified the organisms as *Nocardia cyriacigeorgica* (n=2), *N. farcinica* (n=1) and *Streptomyces albus* (n=1). Among PCR positive patients, 4 were suffering from chronic broncho-pneumonia and one patient had co-infection of *Klebsiella pneumoniae* and *Nocardia cyriacigeorgica*. The results of sequencing confirmed the accuracy of PCR assay (GeneBank accession numbers: MK968270, MK968271, MK968277, MN043685).

Characteristics of study population and multiplex PCR sensitivity assessment: From four PCR positive patients, two were positive in direct smear (partially acid-fast and Gram staining) and took co-trimoxazole before specimen collection. This may be the reason for negative result of culture in this patient. Three other patients did not use antibiotics prior to the specimen collection. All 4 patients were suffering from lung cavitation or lung abscess. One patient had disseminated nocardiosis, which is caused by *Nocardia*

cyriacigeorgica. This organism was isolated from both brain abscess and BAL specimens.

DISCUSSION

This study was the first pilot study for direct-detection of *Nocardia*, *Streptomyces* and *Rhodococcus* genera infections in respiratory clinical specimens using multiplex-PCR method. We detected three cases of infection with *Nocardia* spp. as well as one case of pulmonary infection by *Streptomyces* in HIV-infected patients. The results were confirmed by DNA sequencing. In addition, the sensitivity of this PCR for culture negative samples was demonstrated to be high; the results demonstrated that our primers have high efficiency for identification of *Nocardia* and *Streptomyces* from clinical specimens. It appears that this method is not inhibited by natural inhibitors within the specimens.

The slow growing rate of these organisms, antibiotic consumption before sample collection and time consuming phenotypical tests mean a

delay in treatment, which increases the mortality rate among HIV-infected cases (18,19). Rapid identification in early stages of infection and selection of suitable antibiotics increase the success rate for treatment (20). Therefore, it is important to use molecular techniques as rapid and accurate methods for identification of these agents from clinical specimens to save the time and improve therapy.

In our study, three nocardiosis patients and one *Streptomyces* infected patients showed symptoms at presentation. One of the patients with nocardiosis, one had used co-trimoxazole before collecting the specimens. In clinical samples (especially cerebral and skin abscesses samples) growth of bacteria can be postponed or inhibited by pre-sampling antibiotic consumption. Molecular tests are independent of bacterial cell growth and could be remedial in correct diagnosis of bacteria. Also, one of the patients in this study had co-infection of *Nocardia* with *Klebsiella pneumoniae*. In previous studies, co-infection of *Nocardia* with other bacterial pathogens was reported in 10-30% of patients (1, 21-22). *N. cyriacigeorgica* appears to be the most frequent *Nocardia* species isolated from Iranian patients. It is intrinsically resistant to ciprofloxacin, one of the therapeutic choices for respiratory tract infections (23,24). Early detection of *N. cyriacigeorgica* in clinical samples can lead physicians to choose the correct therapy. Brain abscesses is a life-threatening infection and with 40-50% mortality (25). The result of culture for BAL was negative in a patient with brain abscess, while multiplex PCR detected the causative as *N. cyriarogeorgica*. In follow-up, after anti-nocardiosis treatment of co-trimoxazole, the brain abscess was diminished, indicating that multiplex PCR improved diagnosis and treatment.

In this study, *N. farcinica* strain was detected by multiplex-PCR method, while the culture was negative for the specimen of the same patient. High rate of resistance to antibiotics such as TMP-SXT has been reported among *N. farcinica* isolates (26). Therefore, rapid detection of this species is very important in order to prevent treatment failure. In follow-up, after diagnosis of *N. farcinica*, the treatment was changed from TMP-SXT to imipenem and subsequently the

respiratory signs of the patient improved. It has been suggested that recurrence of nocardiosis is common and in several studies it has been shown that recurrence is due to cell wall deficient bacterial cells, which may not be identifiable in culture (27-29). Moreover, *Nocardia* infections show similar signs to Parkinson's disease (30-31); therefore, molecular diagnostic methods can easily identify the infectious agent from this nervous system disease.

Pulmonary infection by *Streptomyces* has been increasing due to immune deficiency in recent years (32). The clinical signs of *Streptomyces* infection mimics tuberculosis (32), and as there are differences between the methods used for processing and culturing *Streptomyces* and *Mycobacterium tuberculosis*, misdiagnosis of these two infections may occur. This may be complicating treatment as the choices of treatment are also different. In our study *S. albus* infection case showed symptoms similar to tuberculosis (presence of granulomas) (32). Anti-tuberculosis regimen is not effective for treatment of infection with this bacterium. After getting the positive multiplex-PCR result for *S. albus*, treatment was started using imipenem. Therefore, multiplex-PCR was useful for the timely selection of the correct drug regimen and preventing treatment failure.

Although *Rhodococcus equi* was not detected in our study, it is very important in immune deficiency and people working with animals (9); one third of patients who are infected by *R. equi* have a history of contact with horses or pigs. Transmission has also been reported during handling and working with clinical samples (5). Therefore, rapid detection of this bacteria is needed in high risk patients and those in contact with contaminated sources.

Therefore, molecular methods can differentiate these agents that are completely different in laboratory detection and clinical treatment but very similar in clinical signs.

In conclusion, new emerging pathogens such as *Nocardia*, *Streptomyces* and *Rhodococcus* are being isolated from clinical samples more frequently in recent years due to increases in immune deficiency diseases like HIV infections. Improvement of diagnostic methods in screening and identification of these bacterial infections are

highly demanded. *Nocardia* genus has had more attention and been studied more, but *Streptomyces* and *Rhodococcus* species also are increasing. In this study, we designed a novel multiplex PCR for detection of infected cases with *Nocardia*, *Streptomyces* and *Rhodococcus* species for the first time. The results of our study are equivalent or may be better than conventional or current in-house PCR methods. The high specificity (85.7%) and sensitivity (100%) of this method suggest that the development of this multiplex-PCR is a reliable diagnostic tool for direct detection of *Nocardia*, *Streptomyces* and *Rhodococcus* infections from BAL and possibly other clinical specimens.

ACKNOWLEDGMENTS

The authors are grateful to Office of Vice-chancellor for Research of Tehran University of Medical Sciences for the support of the current study (grant number: 36924).

REFERENCES

1. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ, Jr. 2006. Clinical and laboratory features of the *Nocardia* spp. based on current molecular taxonomy. *Clin Microbiol Rev* 19:259–282.
2. Coussement J, Lebeaux D, van Delden C, Guillot H, Freund R, Marbus S, Melica G, Van Wijngaerden E, Douvry B, Van Laecke S, Vuotto F, Tricot L, Fernández-Ruiz M, Dantal J, Hirzel C, Jais J, Rodriguez-Nava V, Lortholary O, Jacobs F. 2016. *Nocardia* infection in solid organ transplant recipients: multicenter European case-control study. *Clin Infect Dis* 63:338–345.
3. Rahdar HA, Azadi D, Shojaei H, Daei-Naser A. Molecular analysis and species diversity of *Nocardia* in the hospital environment in a developing country, a potential health hazard. *Journal of medical microbiology*. 2017 Mar 23;66(3):334-41.
4. Kapadia M, Rolston KV, Han XY. Invasive *Streptomyces* infections: six cases and literature review. *American Journal of Clinical Pathology*. 2007 Apr 1;127(4):619-24.
5. Majidzadeh M, Fatahi-Bafghi M. Current taxonomy of *Rhodococcus* species and their role in infections. *European Journal of Clinical Microbiology & Infectious Diseases*. 2018;37(11):2045-62.
6. Bell KS, Philp JC, Aw DW, Christofi N. The genus *Rhodococcus*. *Journal of Applied Microbiology*. 1998;85(2):195-210.
7. Witkowski L, Rzewuska M, Takai S, Kizerwetter-Świda M, Kita J. Molecular epidemiology of *Rhodococcus equi* in slaughtered swine, cattle and horses in Poland. *BMC microbiology*. 2016;16(1):98.
8. Kedlaya I, Ing MB, Wong SS. *Rhodococcus equi* infections in immunocompetent hosts: case report and review. *Clinical infectious diseases*. 2001;32(3):e39-46.
9. Weinstock DM, Brown AE. *Rhodococcus equi*: an emerging pathogen. *Clinical Infectious Diseases*. 2002 May 15;34(10):1379-85.
10. de Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). *Antiviral research*. 2010 Jan 1;85(1):75-90.
11. Chaudhry SI, Greenspan JS. Actinomycosis in HIV infection: a review of a rare complication. *International journal of STD & AIDS*. 2000 Jun 1;11(6):349-55.
12. Keikha M. *Williamsia* spp. are emerging opportunistic bacteria. *New microbes and new infections*. 2018;21:88-9.
13. Coussement J, Lebeaux D, Rouzaud C, Lortholary O. *Nocardia* infections in solid organ and hematopoietic stem cell transplant recipients. *Curr Opin Infect Dis* 2017; 30(6): 545–51.
14. Coussement J, Lebeaux D, El Bizri N, Claes V, Kohnen M, Steensels D, Étienne I, Salord H, Bergeron E, Rodriguez-Nava V. *Nocardia* polymerase chain reaction (PCR)-based assay performed on bronchoalveolar lavage fluid after lung transplantation: A prospective pilot study. *PloS one*. 2019 Feb 25;14(2):e0211989.
15. Rouzaud C, Rodriguez-Nava V, Catherinot E, Méchaï F, Bergeron E, Farfour E, Scemla A,

- Poirée S, Delavaud C, Mathieu D, Durupt S. Clinical assessment of a Nocardia PCR-based assay for diagnosis of nocardiosis. *Journal of clinical microbiology*. 2018 Jun 1;56(6):e00002-18.
16. Laurent FJ, Provost F, Boiron P. Rapid Identification of Clinically Relevant Nocardia Species to Genus Level by 16S rRNA Gene PCR. *Journal of clinical microbiology*. 1999 Jan 1;37(1):99-102.
17. Arriaga JM, Cohen ND, Derr JN, Chaffin MK, Martens RJ. Detection of Rhodococcus equi by polymerase chain reaction using species-specific nonproprietary primers. *Journal of veterinary diagnostic investigation*. 2002 Jul;14(4):347-53.
18. Lucas, S. B., A. Hounnoun, C. Peacock, A. Beaumel, A. Kadio, and K. M. De Cock. 1994. Nocardiosis in HIV-positive patients: an autopsy study in West Africa. *Tuber. Lung Dis*. 75:301-307.
19. Reis, M. A., R. S. Costa, and A. S. Ferraz. 1995. Causes of death in renal transplant recipients: a study of 102 autopsies from 1968 to 1991. *J. R. Soc. Med*. 88:24-27.
20. McNeil, M. M., and J. M. Brown. 1994. The medically important aerobic actinomycetes: epidemiology and microbiology. *Clin. Microbiol. Rev*. 7:357-417.
21. Minero MV, Cercenado MME, Rabadan PM, Bouza E, Munoz P. 2009. Nocardiosis at the turn of the century. *Medicine (Baltimore)* 88:250-261.
22. Ambrosioni J, Lew D, Garbino J. 2010. Nocardiosis: updated clinical review and experience at a tertiary center. *Infection* 38:89-97.
23. Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxicillin. *Journal of Antimicrobial Chemotherapy*. 1986 Nov 1;18(Supplement D):133-8.
24. Williams JH. Fluoroquinolones for respiratory infections: too valuable to overuse. *Chest*. 2001 Dec 1;120(6):1771-5.
25. Mamelak AN, Obana WG, Flaherty JF, et al. Nocardial brain abscess: treatment strategies and factors influencing outcome. *Neurosurgery* 1994; 35:622-631.
26. Zhao P, Zhang X, Du P, Li G, Li L, Li Z. Susceptibility profiles of Nocardia spp. to antimicrobial and antituberculous agents detected by a microplate Alamar Blue assay. *Scientific reports*. 2017 Mar 2;7:43660.
27. Beaman, B. L. 1981. The possible role of L-phase variants of Nocardia in chronic infections. *Zentbl. Bakteriologie. Mikrobiol. Hyg. Abt. Suppl.* 11:221-227.
28. Beaman, B. L. 1982. Nocardiosis: role of the cell deficient state of Nocardia, p. 231-255. In G. J. Domingue (ed.), Cell wall defective bacteria: basic principles and clinical significance. Addison-Wesley Publishing Co., Inc., Reading, Mass.
29. Beaman, B. L. 1984. The cell wall as a determinant of pathogenicity in Nocardia: the role of L-forms in pathogenesis, p. 89-104. In L. Ortiz-Ortiz, L. F. Bojalil, and V. Yakoleff (ed.), Biological, biochemical and biomedical aspects of actinomycetes. Academic Press, Orlando, Fla.
30. Chapman, G., B. L. Beaman, D. A. Loeffler, D. M. Camp, E. F. Domino, D. W. Dickson, W. G. Ellis, I. Chen, S. E. Bachus, and P. A. Le Witt. 2003. *In situ* hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys and in Lewy body-containing human brain specimens. *Exp. Neurol.* 184:715-725.
31. Diaz-Corrales, F. J., C. Colasante, Q. Contreras, M. Puig, J. A. Serrano, L. Hernandez, and B. L. Beaman. 2004. Nocardia otitidiscaviarum (GAM-5) induces parkinsonian-like alterations in mouse. *Braz. J. Med. Biol. Res.* 37:539-548.
32. Riviere E, Neau D, Roux X, Lippa N, Roger-Schmeltz J, Mercie P, Longy-Boursier M. Pulmonary streptomyces infection in patient with sarcoidosis, France, 2012. *Emerging infectious diseases*. 2012 Nov;18(11):1907.